Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

Authors

  • Monty A. Silverdale MRCP, PhD,

    Corresponding author
    1. Department of Neurology, Hope Hospital, Salford, Manchester, United Kingdom
    2. Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom
    • Hope Hospital, Stott Lane, Salford, Manchester, M6 8HD, United Kingdom
    Search for more papers by this author
  • S.L. Nicholson PhD,

    1. Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom
    Search for more papers by this author
  • A.R. Crossman DSc,

    1. Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom
    2. Motac Neuroscience Ltd., Williams House, Manchester Science Park, Manchester, United Kingdom
    Search for more papers by this author
  • J.M. Brotchie PhD

    1. Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
    Search for more papers by this author

Abstract

Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease. © 2004 Movement Disorder Society

Ancillary